Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for John R. Hallal
149.80
+0.75 (0.50%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 147.30 - 154.11
52 week 87.01 - 185.43
Open 149.27
Vol / Avg. 2.30M/2.14M
Mkt cap 29.63B
P/E 118.13
Div/yield     -
EPS 1.27
Shares 197.83M
Beta 0.47
Inst. own 97%
May 5, 2014
Alexion Pharmaceuticals Annual Shareholder Meeting (Estimated) Add to calendar
Apr 24, 2014
Q1 2014 Alexion Pharmaceuticals, Inc. Earnings Conference Call - 10:00AM EDT - Add to calendar
Apr 24, 2014
Q1 2014 Alexion Pharmaceuticals, Inc. Earnings Release - 9:30AM EDT - Add to calendar
Mar 12, 2014
Alexion Pharmaceuticals, Inc. at Barclays Healthcare Conference
Mar 10, 2014
Alexion Pharmaceuticals, Inc. at EBD BIO-Europe Spring
Mar 4, 2014
Alexion Pharmaceuticals, Inc. at Cowen Health Care Conference
Jan 30, 2014
Q4 2013 Alexion Pharmaceuticals Earnings Conference Call - Webcast
Jan 30, 2014
Q4 2013 Alexion Pharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -4.30% 16.30%
Operating margin 31.24% 34.04%
EBITD margin - 38.96%
Return on average assets -2.39% 8.53%
Return on average equity -3.22% 11.62%
Employees 1,774 -
CDP Score - -

Address

352 Knotter Drive
CHESHIRE, CT 06410
United States - Map
+1-203-2722596 (Phone)
+1-203-2718198 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.

Officers and directors

Max E. Link Ph.D. Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Leonard Bell M.D. Chief Executive Officer, Treasurer, Director
Age: 54
Bio & Compensation  - Reuters
Vikas Sinha CPA Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Stephen P. Squinto Ph.D. Chief Global Operations Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Senior Vice President
Age: 54
Bio & Compensation  - Reuters
David L. Hallal Executive Vice President, Chief Commercial Officer
Age: 46
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 57
Bio & Compensation  - Reuters
John B. Moriarty J.D. Senior Vice President, General Counsel
Age: 46
Bio & Compensation  - Reuters
Saqib Islam J.D. Senior Vice President, Chief Strategy and Portfolio Officer
Bio & Compensation  - Reuters
Frank J. Wright Senior Vice President; President of Alexion Pharma International Sarl
Age: 66
Bio & Compensation  - Reuters